39 search results for: long-term
Gastro Forum 2025 | EoE: How Far We've Come
Prof. Salvatore Oliva and Dr. Milli Gupta discuss the evolution in understanding EoE and the impact of chronic, underlying type 2 inflammation.
Digestive Disease Week 2024 | Washington D.C.
Join ADVENT at the Digestive Disease Week 2024 Congress and visit the Sanofi and Regeneron Medical Booth # 1707.
KOL Video Interview – Dr. Eric Simpson
In this exclusive KOL interview, Dr. Eric Simpson explores the cumulative, long-term impact of atopic dermatitis and highlights the potential benefits of initiating treatment early to help manage disease burden.
ADVENT On Air | Charting a New Course: The Frontier of Early Intervention and Disease Modification in AD
Join Drs. April Armstrong and Lisa Beck for a conversation around the long-term burden and effects of AD. They will discuss the underlying pathophysiology of AD and how early intervention and disease modification may impact disease course.
The Burden of a Lifetime: Can Disease Modification Rewrite the Narrative of Atopic Dermatitis?
Join Professors Jean-David Bouaziz, Amy Paller, and Alan Irvine for a dynamic presentation on the multifaceted burden of atopic dermatitis, the evolving concept of disease modification, and how targeted systemic therapies may help improve long-term patient outcomes.
Current and Emerging Therapeutic Options for Children With Atopic Dermatitis
In this video of the October 2024 ADVENT symposium at EAPS in Vienna, Austria, Dr Perla Lansang reviews the current and emerging treatment options for children with AD uncontrolled with topical therapy, including a summary of recent long-term data for advanced systemic therapies
Digging Deeper: Reducing Non-Atopic Comorbidities and Multidimensional Disease Burden
In this video from the April 2025 WCPD symposium, Dr Paula Luna discusses the multidimensional disease burden in pediatric patients with AD and the data regarding how early intervention may lead to long-term disease control and a reduced risk of developing non-atopic comorbidities.
Both Clinical and Subclinical Disease Control Are Important to Achieve Disease Modification in AD
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr. Eric Simpson explains how both clinical and subclinical disease control are critical for achieving true disease modification in atopic dermatitis, emphasizing the role of biomarkers in predicting long-term outcomes and guiding treatment decisions.
Unlocking Better Outcomes: Strategies for Early Diagnosis and Effective Management in Pediatric EoE Patients
Pediatric gastroenterology experts Dr Carolina Gutiérrez Junquera and Dr Christos Tzivinikos where they discuss the importance of early identification and management of pediatric EoE to improve long-term outcomes. They highlight clinical data and discuss their practical experiences with pediatric EoE, including their perspectives on co-occurring type 2 inflammatory diseases, the chronic nature of EoE, and the future of EoE research and therapeutic development.
ADVENT at ESPGHAN 2025 | Unlocking Better Outcomes: Strategies for Early Diagnosis and Effective Management in Pediatric EoE Patients
In support of World Eosinophilic Esophagitis Day, this ADVENT symposium features pediatric gastroenterology experts Dr Carolina Gutiérrez Junquera and Dr Christos Tzivinikos where they discuss the importance of early identification and management of pediatric EoE to improve long-term outcomes. They highlight clinical data and discuss their practical experiences with pediatric EoE, including their perspectives on co-occurring type 2 inflammatory diseases, the chronic nature of EoE, and the future of EoE research and therapeutic development.
Bridging the Gap in EoE: Innovative Strategies for Seamless Transition of Care
Join leading experts in EoE, Thomas Greuter, MD, Edoardo Vincenzo Savarino, MD, PhD, and Carla Giordano, MD, PhD, as they use a case-based approach to explore the impact of chronic type 2 inflammation in EoE and outline strategies for optimizing transition of care and monitoring disease progression. They review the latest clinical evidence on therapeutic management and share insights from their own practice to support shared decision-making in the long-term care of EoE.
The Benefits of Early Intervention in AD: More Than Skin Deep
Many AD treatment goals focus on clinical manifestations, so that if a patient is free of lesions, their disease is considered well controlled. However, the inflammatory process underlying AD reaches far beyond the skin, affecting patients in unique ways at different stages of their lives. Education on the importance of treating AD beyond the skin and altering the treatment approach to fit the individual patient will help improve clinical management and reduce long-term patient burden.
